Themis Medicare Share price

Themis Chemicals Limited was incorporated in 1969 as aLimited Company in the form of a Joint Venture between M/sChemosyn Private Limited and Medimpex Trading Company Ltd.(Medimpex). The joint venture had technical and financialparticipation by Medimpex a Hungarian trading company forpharmaceuticals products.Themis Chemicals Limited was incorporated with the aim ofmanufacturing and marketing life saving drugs and theirformulations.In 1983-84 Mr Shantilal D. Patel and Mr. K.T. Lakdawala(one of the promoters of Chemosyn Pvt. Ltd.) took over themanagement of the Company by taking over the controllingshare in the Company from Chemosyn Private Ltd. TheCompany now operates as a joint venture between Medimpexand the S.D. Pate Family. Since 1983-84 the Company hasbeen managed by Dr. Dinesh S. Patel Mrs. Jayashree D.Patel and other professionals under the guidance of Mr.S.D. Patel Mr.K.T.Lakdawala and other members of theBoard.In 1971 TCL started with the manufacture of Vitamin B12(Cyanocobalamine) using anaerobic non-sterile fermentationtechnology. They were only the second Company in the worldto manufacture this product.In the early 1970s the Company introduced formulations ofthe anti-tuberculosis drug Ethambutol Hydrochloride in theIndian Market. Subsequently the Company ventured into themanufacture of formulations for various therapeutic groups.The Company has also developed the technology for theproduction of antibiotics such as Gentamycin Rifampicinand Sisomicin using in-house fermentation technology. TCLis engaged in the production of high technology SyntheticBulk Drugs like Ethambutol Pyrazinamide Pyrithioxine andPhenylglycine derivatives.At present the Company is engaged in manufacturing andselling of synthetic bulk drugs and formulations. TCLoperates in the therapeutic segments of antituberculosiscerebroactivators bronchodilators antiasthmaticanesthetic and other segments.The antituberculosis bulk drugs and formulations constituteabout 60% of the turnover. TCL has a wide range of antituberculosis drugs. The company ranks fourth in terms ofturnover in this market (SOURCE : ORG Retail Survey Audit(August 1994). The remaining turnover is made of otherbulk drugs bulk drug intermediates and formulations in theanesthetic appetite stimulant bronohodilator and othertherapeutic groups. The growth rates for the Company andthe market for some of the segments that it operates in aregiven below: Market growth Brand growth Market rate rate shareEthambutol group 7.3% 28.7% 20.9%Rifampicin combinations group 10.6% 52.9% 6.7%Terbutaline group 27.8% 65.6% 0.5%SOURCE : ORG Retail Survey Audit (August 1994)Some of the drugs introduced in the last year have been;Hemolok - under license from Usolje SibirskyHimpharmkombinat (A Russian Institute). Centoblok - underlicense from Central Drug Research Institute (CDRI)-Lucknow.The Company has also started exporting `Fumagillin'' anantibacterial product for veterinary use for which it hasa confirmed buy back arrangement with Chinoin of Hungary.The Company seeks to introduce new technology with the aimto produce the latest drugs at competitive prices. Forthis purpose the Company has a Research and DevelopmentCentre which is approved by the Department of Science andTechnology Government of India so as to keep pace withthe newer developments in the field of biotechnologysynthetic bulk drugs natural products and formulations.The research centre works in close co-operation with thevarious reputed Research Laboratories of the country. TheCompany has not had any strike/lockout in last 20 years inany of its plants.PRESENT ACTIVITIESThe company has manufacturing facilities located at Vapiand Hyderabad. The plant at Vapi manufacturesintermediaries and bulk drugs for the anti tuberculosissegment. Besides this it manufactures variousformulations in the tablet form for anti tuberculosis andother therapeutic segments. This plant also undertakessome contract manufacturing.The facility at Hyderabad has been taken on a subleasearrangement from an associate concern. This facilitymanufactures formulations for various segments in thetablet injectable and syrup forms.MAIN OBJECTS OF THE COMPANYThe main objects of the Company as set out in theMemorandum & Articles of Association and inter aliainclude;1) To carry on business as manufacturers of all kinds ofdrugs pharmaceuticals chemicals fermentation productsnatural products synthetic products feed supplementscosmetics etc.2) To develop and to acquire technical know how receiptsand information to manufacture and right to process andmanufacture drugs pharmaceuticals and fine chemicals ofall kinds cosmetics natural and synthetic productsfermentation products and feed supplements of all kindsand of all forms and to enter into arrangements for use oracquiring proprietary rights of trademarks patentsregarding above.3) To carry on business as buyers sellors and dealers inall kinds of medicines and medicinal preparations drugschemicals natural and synthetic products fermentationproducts feed supplements and cosmetics by wholesale andretail.4) To acquire by purchase locally or by import or otherwisemanufacture for sale locally or by export or forconsumption or use by the company or otherwise for tradein all goods and articles usually used in the manufactureof drugs pharmaceuticals chemicals fermentationproducts natural and synthetic products feed supplementsextracts etc.5) To carry on the business of export and import of drugschemicals natural and synthetic products feed supplementsand cosmetics in all kinds and all forms.SUBSIDIARIESThe Company does not have any subsidiaries.